M Arnedos1, S Drury2, M Afentakis3, R A'Hern4, M Hills3, J Salter1, I E Smith5, J S Reis-Filho6, M Dowsett7. 1. Breast Cancer Unit, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France. 2. NE Thames Regional Genetics Laboratory, Great Ormond Street Hospital, London. 3. Academic Department of Biochemistry, Royal Marsden Hospital, London. 4. Clinical Trials and Statistics Unit, The Institute of Cancer Research, London. 5. Clinical Trials and Statistics Unit, The Institute of Cancer Research, London; Breast Unit. 6. Memorial Sloan-Kettering Cancer Centre, New York, USA. 7. Breast Cancer Unit, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France; NE Thames Regional Genetics Laboratory, Great Ormond Street Hospital, London. Electronic address: mitch.dowsett@icr.ac.uk.
Abstract
BACKGROUND: The purpose of this study was to identify any differences in key biomarkers associated with estrogen action between biopsies taken at diagnosis and at recurrence or progression during treatment with an aromatase inhibitor (AI). PATIENTS AND METHODS: Patients were retrospectively identified from a clinical database as having relapsed or progressed during AI treatment. Immunohistochemistry was carried out against estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2), insulin-like growth factor type-1 receptor (IGF1R), insulin receptor substrate-1 (IRS-1), stathmin, phosphatase and tensin homolog and Ki67. RESULTS: Fifty-five pairs of samples were identified with ER- and/or PgR-positive diseases. Four (7%) patients were ER-negative at progression. Overall, PgR levels were lower in the recurrence sample, but 35% of cases remained positive. IGF1R levels decreased significantly. There were no substantial changes in HER2, IRS-1 or stathmin levels to indicate a role in resistance. Higher Ki67 levels at resistance indicate more proliferative disease. CONCLUSIONS: The phenotype of AI-recurrent lesions shows high between-tumour heterogeneity. There is evidence of an increase in Ki67, a reduction in IGF1R and a loss of ER expression in some individuals and some activation of growth factor signalling pathways that may explain resistance in individuals and merit treatment targeted to those pathways. Biopsy at recurrence will be necessary to identify the relevant target for individuals.
BACKGROUND: The purpose of this study was to identify any differences in key biomarkers associated with estrogen action between biopsies taken at diagnosis and at recurrence or progression during treatment with an aromatase inhibitor (AI). PATIENTS AND METHODS: Patients were retrospectively identified from a clinical database as having relapsed or progressed during AI treatment. Immunohistochemistry was carried out against estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2), insulin-like growth factor type-1 receptor (IGF1R), insulin receptor substrate-1 (IRS-1), stathmin, phosphatase and tensin homolog and Ki67. RESULTS: Fifty-five pairs of samples were identified with ER- and/or PgR-positive diseases. Four (7%) patients were ER-negative at progression. Overall, PgR levels were lower in the recurrence sample, but 35% of cases remained positive. IGF1R levels decreased significantly. There were no substantial changes in HER2, IRS-1 or stathmin levels to indicate a role in resistance. Higher Ki67 levels at resistance indicate more proliferative disease. CONCLUSIONS: The phenotype of AI-recurrent lesions shows high between-tumour heterogeneity. There is evidence of an increase in Ki67, a reduction in IGF1R and a loss of ER expression in some individuals and some activation of growth factor signalling pathways that may explain resistance in individuals and merit treatment targeted to those pathways. Biopsy at recurrence will be necessary to identify the relevant target for individuals.
Entities:
Keywords:
aromatase inhibitor; breast cancer; immunohistochemistry; relapse
Authors: José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi Journal: N Engl J Med Date: 2011-12-07 Impact factor: 91.245
Authors: Mitch Dowsett; Steve R Ebbs; J Michael Dixon; Anthony Skene; Clive Griffith; Irene Boeddinghaus; Janine Salter; Simone Detre; Margaret Hills; Susan Ashley; Stephen Francis; Geraldine Walsh; Ian E Smith Journal: J Clin Oncol Date: 2005-03-14 Impact factor: 44.544
Authors: Lao H Saal; Peter Johansson; Karolina Holm; Sofia K Gruvberger-Saal; Qing-Bai She; Matthew Maurer; Susan Koujak; Adolfo A Ferrando; Per Malmström; Lorenzo Memeo; Jorma Isola; Pär-Ola Bendahl; Neal Rosen; Hanina Hibshoosh; Markus Ringnér; Ake Borg; Ramon Parsons Journal: Proc Natl Acad Sci U S A Date: 2007-04-23 Impact factor: 11.205
Authors: Isabel F Pinhel; Fiona A Macneill; Margaret J Hills; Janine Salter; Simone Detre; Roger A'hern; Ashutosh Nerurkar; Peter Osin; Ian E Smith; Mitch Dowsett Journal: Breast Cancer Res Date: 2010-09-28 Impact factor: 6.466
Authors: Smruthi Vijayaraghavan; Merih Guray Durak; Nicole M Kettner; Tuyen Bui; Mehrnoosh Kohansal; Min Jin Ha; Bin Liu; Xiayu Rao; Jing Wang; Min Yi; Jason P W Carey; Xian Chen; T Kris Eckols; Akshara S Raghavendra; Nuhad K Ibrahim; Meghan Sri Karuturi; Stephanie S Watowich; Aysegul Sahin; David J Tweardy; Kelly K Hunt; Debu Tripathy; Khandan Keyomarsi Journal: Clin Cancer Res Date: 2019-03-13 Impact factor: 12.531
Authors: Gaia Schiavon; Sarah Hrebien; Isaac Garcia-Murillas; Rosalind J Cutts; Alex Pearson; Noelia Tarazona; Kerry Fenwick; Iwanka Kozarewa; Elena Lopez-Knowles; Ricardo Ribas; Ashutosh Nerurkar; Peter Osin; Sarat Chandarlapaty; Lesley-Ann Martin; Mitch Dowsett; Ian E Smith; Nicholas C Turner Journal: Sci Transl Med Date: 2015-11-11 Impact factor: 17.956
Authors: Anne Grote; Mahmoud Abbas; Nina Linder; Hans H Kreipe; Johan Lundin; Friedrich Feuerhake Journal: Diagn Pathol Date: 2014-12-19 Impact factor: 2.644
Authors: Stine Hole; Astrid M Pedersen; Susanne K Hansen; Johan Lundqvist; Christina W Yde; Anne E Lykkesfeldt Journal: Int J Oncol Date: 2015-01-26 Impact factor: 5.650
Authors: Eva Juengel; Snigdha Nowaz; Jasmina Makarevi; Iyad Natsheh; Isabella Werner; Karen Nelson; Michael Reiter; Igor Tsaur; Jens Mani; Sebastian Harder; Georg Bartsch; Axel Haferkamp; Roman A Blaheta Journal: Mol Cancer Date: 2014-06-16 Impact factor: 27.401